WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES

Checking

 

Halma plc HLMA

LondonIndustrial conglomeratesFinancials to Mar 31, 2026 · Updated Nov 11, 2026

On Stock Analysis · affiliate link
HLMA financials
Moat score
–
ROIC
14.3%
P/E
35.4
EV/EBIT
26.3
FCF yield
3.1%
Dividend yield
0.7%
Market cap
£13.2B

Moat ranks

Score rankNot ranked
Durability–
Market structureCompetitive
Pricing powermoderate

Balance sheet

3/31/26
£BMar '25Mar '26
Cash0.30.1
Securities0.00.0
Debt0.70.8
Net cash-0.4-0.7
Equity1.92.2
Leverage
Debt / EBITDA
1.23×
Debt / equity
0.37×
Leases (3/31/26)
£108M
Capital
Diluted shares
379M
Book value / share
£5.72
Price / book
6.1×
Net cash / share
−£1.74
Market cap
£13.2B
Enterprise value
£13.8B

Per-share record

Fiscal years and TTM
Scale
£0£2£4£6£8'17'18'19'20'21'22'23'24'256.81'26
Revenue per shareCash flow per share

Key indicators

Latest: H2 '26
IndicatorLatestVs year agoLast 8 halves
Revenue growth14.6%+6.3 pts
Operating margin20.0%+0.9 pts
FCF margin19.0%-4.2 pts
Capex / revenue2.7%+0.0 pts
Gross margin–––
Net margin13.8%+0.1 pts
R&D / revenue–––
Stock pay / revenue–––

Margins and growth from reported quarters; company KPIs as reported in results releases.

About HLMA

Halma owns decentralized safety, environmental measurement, photonics and healthcare businesses. FY2026 revenue was GBP 2.6 billion, led by Environmental & Analysis.

Revenue mix
Environmental & Analysis 40.2%Safety 36.7%Healthcare 23.2%
Timeline
  1. Sep 24, 2026

    Halma raised FY2027 adjusted EBIT margin guidance to 23.5–24%, reflecting operational delivery and product and portfolio mix. Organic revenue growth guidance remains low double digits.

  2. Sep 1, 2026

    Steve Brown became Environmental & Analysis Sector Chief Executive, moving from Healthcare. Marc Ronchetti remains Group Chief Executive.

  3. Sep 2026

    Halma completed the acquisition of the three Pyxis companies for a maximum USD 200 million, extending real-time water-quality monitoring.

  4. Sep 2026

    Bill Stoval became Healthcare Sector Chief Executive, moving from Healthcare Divisional Chief Executive and joining the Executive Board.

  5. Aug 2026

    Halma sold NovaBone for USD 56 million net of disposal costs, exiting bone-graft products with no material disposal gain or loss expected.

Financial record

Fiscal year2017201820192020202120222023202420252026TrendChange 2017–26
Per share (£)
Revenue2.542.843.193.533.474.024.895.375.936.81+11.6%/yr
Cash flow0.460.460.580.670.730.630.681.021.301.27+12.0%/yr
Earnings0.340.410.450.490.540.640.620.710.780.98+12.4%/yr
Free cash flow0.360.370.470.550.620.520.560.881.141.08+12.9%/yr
Capex0.090.080.110.130.110.110.120.140.160.19+8.0%/yr
Dividends0.130.140.150.160.170.180.190.210.220.24+6.7%/yr
Book value2.062.192.593.003.073.704.224.595.015.72+12.0%/yr
Diluted shares (M)379379379379380379379379379379+0.0%/yr
Totals (£B)
Revenue1.01.11.21.31.31.51.92.02.22.6+11.6%/yr
Operating income0.20.20.20.20.20.30.30.40.40.5+13.6%/yr
Net income0.10.20.20.20.20.20.20.30.30.4+12.4%/yr
Free cash flow0.10.10.20.20.20.20.20.30.40.4+12.9%/yr
Buybacks0.00.00.00.00.00.00.00.00.00.0+34.2%/yr
Dividends0.00.10.10.10.10.10.10.10.10.1+6.8%/yr
Net cash-0.2-0.2-0.2-0.3-0.2-0.2-0.5-0.6-0.4-0.7−£0.5B
Margins & returns (%)
Operating margin17.416.818.017.418.318.316.618.118.220.4+3.0 pts
Net margin13.514.314.013.815.416.012.713.213.214.4+0.9 pts
FCF margin14.313.214.615.417.912.911.416.419.315.9+1.6 pts
ROIC13.213.314.412.413.713.411.312.313.614.3+1.1 pts
Return on equity16.718.617.316.217.417.414.715.515.617.2+0.5 pts
R&D % of revenue4.14.44.34.34.24.74.74.34.24.2+0.0 pts
Stock pay % of revenue0.70.80.90.91.01.01.11.11.21.2+0.5 pts
Capex % of revenue3.72.93.53.63.22.62.52.52.62.7-0.9 pts

Change uses 2017 and 2026 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2017 base. Trend shows the fiscal years.

Per-share values use diluted weighted shares.ROIC = operating income × (1 − 22.9% tax rate, the company's own over three fiscal years excluding one-offs) ÷ (equity + debt − cash and current securities). Returns show a dash when their base is negative or under 10% of revenue. Free cash flow = operating cash flow − capex. Debt is all borrowings; net cash counts long-term securities and excludes leases. No trailing-twelve-month column: no complete four quarters end after the last fiscal year.

Moat

Moat scorecard

Moat score–
Strength
–
Confidence
–
Structure
Competitive
Durability
–
Trajectory
–
Pricing power
moderate
Segments
  • Safety36.7%
    Not scored: evidence insufficient
  • Environmental & Analysis40.2%
    Not scored: evidence insufficient
  • Healthcare23.2%
    Not scored: evidence insufficient

Moat claims

No moat claims for this company yet.

Profile change log

  1. Oct 7, 2026 · analyst revision

    Added the US water-regulation timing risk to the Environmental & Analysis market profile: EPA proposed a PFOA/PFOS treatment-compliance extension while retaining monitoring deadlines. Testing demand and treatment capital spending can move at different times; Halma does not disclose a separate PFAS revenue line.

  2. Oct 7, 2026 · business change

    Halma raised FY2027 adjusted EBIT margin guidance to 23.5–24%, reflecting operational delivery and product and portfolio mix. Organic revenue growth guidance remains low double digits.

  3. Oct 7, 2026 · business change

    Bill Stoval became Healthcare Sector Chief Executive, moving from Healthcare Divisional Chief Executive and joining the Executive Board.

  4. Oct 7, 2026 · business change

    Steve Brown became Environmental & Analysis Sector Chief Executive, moving from Healthcare. Marc Ronchetti remains Group Chief Executive.

  5. Oct 7, 2026 · business change

    Halma completed the acquisition of the three Pyxis companies for a maximum USD 200 million, extending real-time water-quality monitoring.

  6. Oct 7, 2026 · business change

    Halma sold NovaBone for USD 56 million net of disposal costs, exiting bone-graft products with no material disposal gain or loss expected.

  7. Oct 7, 2026 · business change

    Halma bought Dreampath Diagnostics for a maximum EUR 279 million, adding automated pathology-sample tracking and storage.

  8. Oct 7, 2026 · business change

    Halma bought Näslund Medical for a maximum USD 45 million, adding cancer-treatment fiducial markers to IZI Medical.

  9. Oct 7, 2026 · business change

    Halma bought itemedical for a maximum EUR 23 million, adding hospital device-data integration to SSG.

  10. Oct 7, 2026 · business change

    Halma sold Cardios for BRL 82 million. The expected GBP 4 million loss reflects currency devaluation since acquisition.

  11. Oct 7, 2026 · business change

    Halma bought Surgistar for USD 90 million, expanding MST’s ophthalmic surgical instruments.

  12. Oct 7, 2026 · business change

    Halma sold Labsphere for USD 42 million. The sale reduces optical calibration exposure; its Chinese entity closed on 16 April.

  13. Oct 7, 2026 · business change

    Halma bought DCR Inspection Systems for GBP 8 million, adding rental and service capability to Minicam.

  14. Oct 7, 2026 · business change

    Nuvonic licensed certain regional products to FluidSmile for GBP 9.9 million and bought a 35% associate interest for the same amount. The licence added GBP 9.3 million one-time operating profit.

  15. Oct 7, 2026 · business change

    Halma sold Texecom for GBP 64.8 million, generating a GBP 34.0 million one-time gain and reducing security-alarm exposure.

  16. Oct 7, 2026 · business change

    Halma sold Fiberguide for GBP 27.6 million before disposal costs, reducing fibre-optic exposure and generating a one-time disposal gain.

  17. Oct 7, 2026 · analyst revision

    Added management, the investment debate and three market profiles. Kept market sizes and shares unreported where no source matches the full segment product mix.

  18. Oct 7, 2026 · analyst revision

    Verified FY2026 segment revenue and retained all three insufficient-evidence assessments. Apollo panel compatibility and Avo co-development show possible product switching costs, but revenue coverage and retention are not disclosed. Removed sector operating-profit shares because sector adjusted profits omit corporate costs; corrected itemedical and Näslund acquisition months from July to June.

  19. Oct 7, 2026 · analyst revision

    The owner changed the industry to Industrial conglomerates because Halma combines decentralized safety, environmental measurement and healthcare businesses in a diversified operating group.

Industry & peers

Peer map

0%10%20%30%40%50%60708090100Moat scoreSUAIEXTMOABTMDT

Hover a point for its values; click a peer to compare. Dashed lines: industry medians.

Environmental measurement and custom photonics

As of Oct 7, 2026
CompetitiveMedium cyclicality

Environmental and resource monitoring, water analysis and treatment instruments, specialist measurement systems and custom optical or photonic subsystems. These are distinct markets; this profile excludes commodity telecom equipment, semiconductor foundries and laboratory research services.

  1. Agilent
  2. Danaher
  3. Thermo Fisher Scientific
  4. Shimadzu
  5. Emerson
  6. Honeywell
2025 leaders, no comparable shares · MarketsandMarkets
StocksMoatGross m.Op. m.
HLMA––20.4%
Industry median450––
Sector median777564.7%23.8%
All stocks median3987653.1%20.0%

Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.

Drivers & risks

Demand drivers
  • Water quality, resource scarcity and pollution rules have a strong long-run effect on monitoring needs. Utility budgets and regulatory enforcement govern when orders turn into sales.
  • Data-centre investment and demand for faster data transfer have a strong effect on custom photonics programmes. Halma’s FY2026 large-customer photonics revenue rose 52%, showing that this part can move faster than environmental instruments.
  • Industrial and infrastructure investment have a moderate to strong effect on gas, process and underground measurement equipment; interest rates and economic confidence can postpone projects.
  • Currency translation is material for global suppliers. Electronics, specialised materials, labour and tariffs affect production costs; customer-owned designs can constrain a manufacturer’s bargaining power.
Risks
  • A major photonics customer can cut spending or redesign a programme. Halma’s largest Environmental & Analysis buyer represented 20% of FY2026 group revenue.
  • Technology change can make an optical design obsolete or move production to another vendor. Avo states that the customer owns the intellectual property.
  • Environmental instruments face competition from broad analytical suppliers and specialist vendors; leadership in one sensing niche does not establish a groupwide market share.
  • Utility funding constraints, slower industrial activity and delayed regulatory treatment deadlines can postpone projects. EPA proposed an optional extension of US PFOA/PFOS compliance to 2031 in May 2026, while keeping monitoring deadlines.
  • Export controls, tariffs and specialised component shortages can raise costs or limit sales; failures in safety-critical measurements can also create liability.

Bulls & bears

Key question · as of Oct 7, 2026

Can Halma keep organic cash generation broad enough to fund acquisitions and sustain margins when its largest photonics customer slows?

Arguments

4 forFaded: weakening or settled4 against

What to watch

  1. 1Organic revenue and adjusted profit growth by sector, with photonics and licence income identified separately.
  2. 2Largest customer revenue share and order intake versus revenue.
  3. 3Operating cash flow, capex, acquisition cash paid and debt, alongside reported return on total invested capital.

Next check: 19 November 2026 half-year results: compare cash generation and sector demand with the September margin upgrade; check Pyxis and Dreampath contribution and disposal results.

Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.